Resectable by radiographic criteria

Consent #1: EUS/FNA Screen

FNA+ Adenocarcinoma
Eligible for Trial

Consent #2: Molecular Profiling Performed

Profile Predictive

Profile Not Predictive

Target Not Identified

2 mo Targeted therapy

Chemo/XRT

Restage

Stable Disease

Surgery

Surgical Specimen
Molecular Profiling

Restage

Profile Predictive

Profile Not Predictive

Target Not Identified

previous XRT

no prior XRT

4 mo of targeted chemo

2 mo of targeted chemo; then chemo/XRT

Targeted chemo/XRT

SMAD 4 intact; No further treatment

SMAD 4 loss; 4 mo. gem

chemo/XRT

4 mo. gem

2 mo of gem, then chemo/XRT

Follow up

*During adjuvant therapy, restaging will be performed after the first 2 months of therapy. Patients with disease progression will come off study and be followed for survival every 6 months.

See Section 2.2.4.3

Figure A: